Avacta previews AVA6103 pharmacokinetic data as sustained-release cancer drug faces first human test
Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.
Features & Analysis
Features & Analysis
Avacta secures single-trial FDA path for AVA6000, but can its low-FAP cancer signal survive a pivotal test?
Avacta Group PLC has agreed a potential full-approval pathway for faridoxorubicin with the United States Food and Drug Administration, while new clinical analyses suggest the drug may work even in tumours with very low FAP expression. The pivotal opportunity is becoming clearer, but Avacta still needs mature progression-free survival data, a development partner and evidence